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family, whose members are implicated in cell proliferation,
differentiation, and death (8). The cytoplasmic tail of Fas
contains a region termed the death domain, which, when
coupled to a caspase cascade by the adapter protein FADD
(MORT-1), can transduce signals leading to apoptosis (9–11).
During an antigen-specific immune response, Fas is upregulated and FasL is induced on activated T cells, which then
may undergo Fas兾FasL-mediated cell autonomous death (12,
13). Fas兾FasL-mediated cell death has been suggested as a
mechanism for the disappearance of effector cells after an
immune response, a phenomenon termed activation-induced
cell death (AICD) (12, 14, 15). Mice bearing a mutation in the
Fas gene (lpr mice) and children with defective Fas function
develop massive lymphadenopathy and autoimmune symptoms, demonstrating a role for Fas in lymphocyte homeostasis
and peripheral tolerance (16–23). Paradoxically, ligation of
Fas also can costimulate the proliferation of anti-CD3activated human peripheral blood T cells (24–26). Thus, Fas
engagement can both induce death and promote proliferation
in T cells. Little is known regarding what regulates the outcome
of Fas signaling. The effects of Fas engagement on naı̈ve and
memory T cells, which constitute the majority of the peripheral
T cell pool, have not been compared.
To investigate the outcome of Fas signaling in naı̈ve and
memory T cells, we examined the effects of Fas engagement
within two systems of freshly isolated mouse T cells. We found
that under identical stimulation conditions, naı̈ve and memory
CD4⫹ T cells, defined by well established surface phenotypes
and isolated from the same starting population, undergo
opposite responses when subjected to Fas ligation. Fas engagement induced apoptosis in naı̈ve cells, but costimulated
the proliferation of memory T cells. Furthermore, CD28mediated costimulation or T helper (Th)1 and Th2 differentiation cytokines altered the response of naı̈ve T cells, allowing
them to be costimulated by Fas ligation. We used a T cell
receptor (TCR) transgenic model to study an in vivo system of
antigen-specific T cell memory. We examined the peripheral
CD4⫹ population in mice bearing a transgenic TCR specific
for hen egg lysozyme (HEL) peptide (27), to investigate
changes in Fas responsiveness induced by antigen-driven generation of a memory population. The results confirmed that
the physiological response of CD4⫹ T cells to Fas is determined by previous antigenic history and availability of costimulation. Our findings suggest a model for Fas regulation of
peripheral tolerance, as well as mechanisms for failure of
peripheral tolerance and autoreactivity.

ABSTRACT
Engagement of Fas (APO-1, CD95), a member of the tumor necrosis factor receptor superfamily, can
induce apoptotic cell death. However, Fas engagement also can
costimulate lymphocyte proliferation. The physiologic regulation of these two outcomes is poorly understood. Here, we
have used two systems, the first in vitro and the second in vivo,
to demonstrate that naı̈ve and memory CD4ⴙ T cells display
dichotomous responses to Fas ligation. Naı̈ve CD4ⴙ T cells
(CD44lo, CD45RBⴙ, CD62Lⴙ) die as a consequence of Fas
ligation in the presence of anti-CD3 antibody, whereas memory T cells (CD44hi, CD45RBⴚ, CD62Lⴚ), freshly isolated
from the same starting population and subjected to the same
stimulation conditions, are costimulated to proliferate by Fas
ligation. In vitro, we demonstrate that CD28-mediated signals
or T helper 1 and T helper 2 differentiation cytokines alter the
response of naı̈ve T cells, but not of memory T cells, to Fas
ligation. In vivo experiments in hen egg lysozyme (HEL) T cell
receptor transgenic mice show that CD4ⴙ T cells from HELnaı̈ve mice are killed by Fas ligation, but CD4ⴙ T cells from
long-term HEL-exposed mice are costimulated by Fas ligation.
Thus, the physiological outcome of Fas ligation in CD4ⴙ T
cells is determined primarily by the antigenic history of the T
cell.
The peripheral T cell pool is highly heterogeneous, consisting
of multiple subpopulations distinguished by differences in
phenotype and function. Lymphocytes in the periphery may be
in one of three states, naı̈ve, effector, or memory, depending
on their history of exposure to antigen (1–3). Naı̈ve cells have
never been exposed to specific antigens and are characterized
by expression of CD62L (MEL-14, L-selectin) and the CD45
high-molecular-weight isoforms (CD45RA兾B兾C), and by low
CD44 expression. Effector lymphocytes are recently antigenactivated cells and express activation markers including CD69,
CD25 (IL-2 receptor ␣), and high CD44. Memory cells are
antigen-exposed cells that persist long after the primary immune response. Phenotypically, memory cells are CD62L⫺
CD45RA兾B兾Clo CD44hi and have lost the expression of activation markers such as CD25 and CD69, but have increased
expression of the intracellular survival molecules Bcl-2 and
Bcl-xL. Functionally, memory cells accumulate with age and
antigen exposure, are present at higher precursor frequencies,
have a lower activation threshold, and may express differentiated cytokine patterns when reactivated (1–3). CD4⫹ memory cells may require the continuous presence of low amounts
of antigen to persist and remain in a continuous, subproliferative activation state (4).
Some effector cells and other T cells with activated phenotypes, such as many clones and hybridomas, are sensitive to
Fas-induced death (5–7). Fas is a member of the tumor
necrosis factor receptor兾nerve growth factor receptor super-
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TCR, T cell receptor; HEL, hen egg lysozyme.
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ratory. 3A9 transgenic mice (B10BR animals transgenic for an
␣␤-TCR specific for HEL in the context of I-Ak) (27) were
bred and maintained in our colony at Dartmouth College in
compliance with state, federal, and institutional guidelines.
Purification of Naı̈ve and Memory CD4ⴙ T Cell Populations. T cell populations were purified from single-cell suspensions of pooled murine lymphoid tissues (spleens and
cervical, axillary, and inguinal lymph nodes). Naı̈ve cells were
obtained by negative selection on CD4 T cell columns (Biotex
Laboratories, Edmonton, Canada), using the manufacturer’s
directions modified by adding anti-CD44 antibody (supernatant from clone IM7.8.1, diluted 1:15) to the antibodies
supplied with the kit. Anti-CD44 antibodies selectively bind to
CD44hi memory兾activated cells and allow them to be retained
in the column and removed from the suspension. Memory cells
were purified by adding 5 g兾ml of sodium azide-free antiCD62L antibodies (PharMingen) to those supplied with the
CD4 column kit. CD62L (MEL 14, L-selectin) is expressed
selectively on naı̈ve cells, and this marker was used to remove
the CD62L⫹ naı̈ve cells from the suspension. Naı̈ve and
memory cells were prepared in parallel from the same starting
population. These negative-selection purification procedures
resulted in cell populations that were ⬎90% CD4⫹ T cells. In
both populations, contaminating cells could be accounted for
by CD8⫺ ␥␦ T cells (2–3%) and natural killer cells (5–7%). B
cells and monocytes were present at less than 1%.
Cell Culture, Antibodies, and Cytokines. The wells of 96well flat-bottomed tissue culture plates were coated with
antibodies by incubating 100 l兾well of PBS containing 1
g兾ml of anti-CD3, with or without anti-Fas and兾or anti-CD28
antibodies at the indicated concentrations, for 1 hr at 37°C, as
described (28). The wells then were washed and the T cells
were plated immediately into the coated wells, at 5 ⫻ 104 cells
per well, in complete RPMI 1640 medium with 5% FCS.
Recombinant mouse IL-2 (10 ng兾ml) (PharMingen), recombinant mouse IL-4 (100 ng兾ml) (PharMingen), or mouse IL-12
(3.5 ng兾ml) (generously provided by M. Rincón), were added
with the cells at the time of plating, only where indicated. In
all figures, data points and error bars represent the average and
SD of triplicate wells, and data shown are representative of a
minimum of three experiments.
Flow Cytometry and Cell Cycle Analyses. Cell phenotypes
were determined by staining cells with anti-CD4, anti-Fas,
anti-CD25, anti-CD69, anti-CD44, anti-CD45RB, and antiCD62L antibodies (PharMingen). Expression of the transgenic
TCR in the 3A9 mice was verified by staining with FITCconjugated anti-V␤8.2. Cell cycle analysis was performed by
permeabilizing and staining the cells with Bauer DNA-staining
solutions containing 0.1% Triton X-100 and 50 g兾ml of
propidium iodide (29). Data were acquired on a Coulter Elite
Epics flow cytometer (Coulter) and analyzed with CELLQUEST
software (Becton Dickinson).
Proliferation Assays. Cells were cultured for 48 or 72 hr, as
described above, and then were pulsed with [3H]thymidine (1
Ci兾well) and cultured for an additional 18 hr. The wells were
harvested onto filters, and the incorporated radiation was
quantitated by a Packard scintillation counter.
Immunization of Transgenic Mice. 3A9 mice were injected
with 50 g HEL peptide emulsified in 200 l incomplete
Freund’s adjuvant s.c. on the back. Draining lymph nodes
(axillary and cervical) were collected 3–4 weeks postinjection.
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not shown). Lymph nodes preferentially recruit naı̈ve T cells
from the peripheral circulation via the expression of L-selectin
(MEL-14, CD62L) receptors on their specialized high endothelial venules (30, 31). Conversely, the spleen is relatively rich
in memory cells, which lack L-selectin expression (3). We
hypothesized that the opposite responses to Fas engagement
could reflect the differential composition of memory vs. naı̈ve
cells in these two tissues. Accordingly, we isolated CD4⫹ T cell
subpopulations from suspensions of pooled spleen and lymph
node cells, using CD44⫹-depleted populations as naı̈ve cells
and CD62L⫹-depleted populations as memory cells. In both
cases, we used negative selection techniques to avoid engaging
any cell surface molecules before cell culture. We studied naı̈ve
and memory populations derived from purified CD4⫹ T cells
to avoid the influence of different ratios of CD4⫹ to CD8⫹
cells. We have used a well characterized phenotypic definition
of ‘‘naı̈ve’’ and ‘‘memory’’ T cells, extensively correlated with
function in the literature (reviewed in refs. 1–3). Naı̈ve cells are
uniformly CD62L⫹, CD44lo, and CD45RB⫹, whereas memory
cells are CD62L⫺, CD44hi, and CD45RB⫺ (Fig. 1). Activated
effector T cells also express high levels of CD44, and recently
activated cells are likely to respond differently from memory
cells. Therefore, we examined both populations for the expression of the activation markers CD69 and CD25 (IL-2
receptor ␣) and found no differences in the percentage of
activated cells in the naı̈ve and memory populations (less than
1% activated cells in either population; Fig. 1). We also
examined preculture cell surface Fas levels, because differences in Fas expression may affect the response to Fas
engagement, and in human peripheral blood T cells, Fas
expression is higher on memory than naı̈ve T cells (32). We
found that mean Fas expression was not significantly different
on naı̈ve and memory mouse T cell populations (Fig. 1),
suggesting that differential responses to Fas ligation would not,
in this instance, reflect different levels of cell surface Fas
expression.
Fas Ligation Inhibits the Proliferative Response of Naı̈ve
Cells, but Costimulates the Proliferation of Memory Cells. We
stimulated freshly isolated naı̈ve or memory peripheral T cells
with anti-CD3, with or without exogenous Fas ligation as
provided by plate-bound anti-Fas antibodies. Fas ligation
inhibited the proliferation of naı̈ve CD4⫹ T cells and costimu-

RESULTS
Characterization of CD4ⴙ T Cell Naı̈ve and Memory Populations in Normal Mice. We investigated the effects of Fas
ligation in mouse T cells purified from spleen or lymph nodes.
Our initial findings showed that splenic T cells stimulated with
anti-CD3 were costimulated by Fas ligation. In contrast, Fas
ligation inhibited the proliferation of lymph node T cells (data

FIG. 1. Phenotypes of purified CD4⫹ naı̈ve and memory cell
populations. Naı̈ve (thin line) and memory (thick line) CD4⫹ cells
were prepared from pooled spleens and lymph nodes from B6 mice by
negative selection, using T cell purification columns. Naı̈ve cells were
purified by removal of CD8⫹, Ig⫹, and CD44⫹ cells. Memory cells
were prepared by removal of CD8⫹, Ig⫹, and CD62L⫹ cells.
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lated the proliferation of memory cells in a dose-dependent
manner (Fig. 2A). To verify that the effect of anti-Fas antibody
was specific, we repeated the experiment with cells from young
(predisease) B6-lpr mice, which lack cell surface Fas expression because of a mutation in the Fas gene (16). As expected,
the proliferation of CD4⫹ naı̈ve and memory cells from lpr
mice was not affected by anti-Fas antibody (Fig. 2B). Both B6
and B6-lpr memory T cells responded more vigorously to
anti-CD3 stimulation than did naı̈ve cells. Interestingly, the
baseline CD3-mediated proliferative response (in the absence
of exogenous Fas ligation) of naı̈ve cells from lpr mice was
higher than that of naı̈ve cells from B6 animals, whereas the
baseline response of memory B6 cells from the two strains was
identical. The cells were plated at very low density to prevent
cell–cell contact in culture, suggesting that the inhibition of the
naı̈ve B6 cells compared with lpr cells may be mediated by cell
autonomous death (Fas兾FasL interactions occurring on a
single cell). In contrast, because there is no difference between
B6 and lpr memory cells, it is possible that Fas-mediated
costimulation is not cell autonomous, but requires exogenous
Fas ligation mediated by antibody (in this case) or cell–cell
interactions (in vivo).
Fas and CD28 Have Opposite Effects on Naı̈ve Cells but
Identical Effects on Memory Cells During CD3-Induced Proliferation. Engagement of the T cell surface molecule CD28
delivers potent costimulatory signals for T cell proliferation
and cytokine production (33–35). We used CD28 ligation
together with anti-CD3 stimulation as a positive control for
costimulation in our system to verify that the naı̈ve populations
retained the ability to be costimulated after the purification
procedure and to compare the levels of memory cell costimulation obtained via Fas and CD28. Naı̈ve cells were extremely
sensitive to CD28 costimulation and were inhibited by Fas
ligation (Fig. 3 A and C). In contrast, memory cells were
costimulated equally well by Fas and CD28 signals (Fig. 3 B
and D). Results are shown after 2 (Fig. 3 A and B) and 3 days
(Fig. 3 C and D) of stimulation; after 4 days in culture, the
costimulated wells were overgrown. The costimulatory effects
persisted throughout the period studied, and no outgrowth was
observed in the cultures of naı̈ve cells treated with anti-Fas
antibodies. Instead, cells with apoptotic morphology accumulated in these wells (Fig. 4A). Thus, naı̈ve cells displayed
opposite responses to Fas and CD28 ligation, but memory cells
responded indistinguishably in terms of costimulated proliferation.
Fas Suppresses Naı̈ve Cell Proliferation by Inducing Apoptotic Death. Fas is known to induce cell autonomous death by
apoptosis in T cell hybridomas and in human T cell clones,

FIG. 2. Fas ligation inhibits naı̈ve CD4⫹ T cell proliferation and
augments memory CD4⫹ T cell proliferation in B6 (A) but not B6-lpr
(B) mice. Naı̈ve (thin lines) and memory (thick lines) CD4⫹ cell
populations were purified as described in Fig. 1 from B6 (A) and B6-lpr
(B) pooled peripheral lymphoid cells and stimulated with 1 g兾ml of
anti-CD3 antibody and indicated concentrations of anti-Fas antibody
for 72 hr. Incorporation of [3H]thymidine was measured as an indicator of proliferation. Engagement of Fas in the absence of anti-CD3
antibody produced no effect.

Proc. Natl. Acad. Sci. USA 96 (1999)

FIG. 3. Fas and CD28 ligation have opposite effects on CD4⫹ naı̈ve
T cell proliferation (A and C) but identical costimulatory effects on
CD4⫹ memory cells (B and D). Purified naı̈ve (A and C) or memory
(B and D) CD4⫹ T cells from B6 mice were cultured with 1 g兾ml of
anti-CD3 antibody and indicated concentrations of anti-CD28 (thin
line) or anti-Fas (thick line) antibody. Kinetics were determined by
harvesting the cells after 48 hr (A and B) or 72 hr (C and D) of
stimulation. Incorporation of [3H]thymidine was measured as an
indicator of proliferation.

malignant T cells, and peripheral activated T cells (5–7).
Inspection of the Fas-treated naı̈ve cells by light microscopy
revealed morphologically apoptotic cells. Conversely, memory
cells cultured with anti-Fas proliferated rapidly and showed no
evidence of increased numbers of dead cells. To determine
whether the inhibition of proliferation in the CD3-stimulated
naı̈ve cells was accompanied by increased apoptotic death, we
analyzed the cell cycle by flow cytometry (29). Apoptosis,
determined by the percentage of cells with less than 2n DNA,
was increased dramatically by Fas ligation in naı̈ve cells (Fig.
4A; apoptosis was increased from 29 to 62% by Fas engagement). In contrast, CD28 ligation decreased the percentage of
naı̈ve apoptotic cells and increased the percentage of cycling
cells (Fig. 4A; apoptosis was decreased from 29 to 8%). The
costimulatory effect of Fas ligation on memory cells was not
accompanied by increased cell death; in fact, in memory cells,
Fas engagement slightly decreased apoptosis, from 23 to 18%
(Fig. 4B). Fas ligation did not increase the percentage of
memory cells in G2兾S (Fig. 4B), although these cells demonstrate increased proliferation as determined by thymidine
incorporation (Figs. 2 A and 3 B and D). These results suggest
that Fas ligation alters the rate of proliferation of memory
cells, rather than the number of cells in cycle at any given time,

FIG. 4. Fas ligation induces apoptotic cell death in naı̈ve but not in
memory CD4⫹ T cells. Naı̈ve (A) or memory (B) cells were stimulated
with 1 g兾ml of anti-CD3 antibody alone (dotted line) or with
anti-CD3 plus 5 g兾ml of anti-CD28 (solid, thin line) or anti-Fas
antibody (thick line) for 48 hr. Cells were permeabilized and stained
with DNA-binding solutions and analyzed by flow cytometry. Apoptotic (⬍2n DNA) cells are those to the left of the gate. For naı̈ve cells
(A), 29% of cells were apoptotic (⬍2n DNA) when stimulated with
anti-CD3 alone, 8% were apoptotic when treated with anti-CD3 and
anti-CD28 antibodies, and 57% were apoptotic when treated with
anti-CD3 and anti-Fas antibodies. For memory cells (B), percentages
were 23, 12, and 18% for anti-CD3 alone, anti-CD3 ⫹ anti-CD28, and
anti-CD3 ⫹ anti-Fas treatments, respectively.
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and show that naı̈ve cells, but not memory cells, undergo
apoptosis in response to Fas ligation.
Differentiation Cytokines and Costimulation Rescue Naı̈ve
Cells from Fas-Induced Death and Render Them Receptive to
Fas-Mediated Costimulation. Clearly, a physiological mechanism is required to rescue newly stimulated naı̈ve cells from
Fas-mediated death or T cell responses to novel antigens would
never develop. We studied the response of naı̈ve and memory
cells to Fas ligation in the presence of prototypical Th1 (36, 37)
or Th2 (38, 39) differentiation cytokines to determine whether
an imposed cytokine bias affected the outcome of Fas ligation.
We found that IL-4 (Th2) or IL-12 (Th1) could shift naı̈ve cells
from being susceptible to Fas-mediated death to being responsive to Fas-dependent costimulation (Fig. 5A). In the presence
of IL-4 and, to a lesser extent, of IL-12, naı̈ve T cells were
rescued from apoptosis and were costimulated by Fas ligation
(Fig. 5A). Thus, the differentiation cytokines did not simply
rescue the naı̈ve cells from Fas-mediated death, but also
conferred the capacity for Fas costimulation. In contrast, the
response of memory cells to Fas ligation was not affected by
exogenous IL-4 or IL-12.
IL-2 is required for T cell proliferation but has also been
implicated in T cell apoptosis (40). In fact, addition of exogenous IL-2 to naı̈ve T cells increased both their proliferation
and Fas-mediated inhibition. Thus, exogenous IL-2, unlike
IL-4 and IL-12, did not confer the capacity to be costimulated
through Fas (Fig. 5B). Costimulation via CD28, however,
mimicked the effect of the differentiation cytokines on naı̈ve
cells and synergized with Fas costimulation in memory cells
(Fig. 5B). Thus, costimulation or an exogenous source of high
levels of Th1兾Th2 differentiation cytokines can shift Fas
signals from death-inducing to costimulation-conferring in
naı̈ve CD4⫹ T cells.
CD4ⴙ T Cells of TCR Transgenic Mice Shift from Sensitivity to Fas-Induced Apoptosis to Responsiveness to FasMediated Costimulation, After Immunization with Peptide.
We used a TCR transgenic mouse model to investigate
whether populations of naı̈ve or memory cells, generated by in
vivo exposure to specific antigen, also would display a dichotomous response to Fas ligation. Unimmunized 3A9 mice,
transgenic for a TCR specific for HEL peptide 46–61, served
as a source of ‘‘naı̈ve’’ T cells (27). Age-matched 3A9 transgenic mice were immunized with a single dose of HEL 46–61
peptide in incomplete Freund’s adjuvant and served as a
source of ‘‘memory’’ cells 4 weeks after immunization. In
contrast to previous experiments, CD4⫹ T cells obtained from
the transgenic mice were not further fractionated according to
phenotype. The entire population of peripheral CD4⫹ T cells
from the uninjected mice was considered ‘‘naı̈ve,’’ and the

FIG. 5. The cytokine environment modulates naı̈ve but not memory CD4⫹ T cell response to Fas ligation. (A) Differentiation cytokines
IL-4 (Th2) and IL-12 (Th1) reverse the Fas responsiveness of naı̈ve
cells but do not affect the Fas responsiveness of memory cells. Naı̈ve
or memory CD4⫹ T cells were stimulated with 1 g兾ml of anti-CD3
alone (open bars) or 5 g兾ml of anti-Fas antibody (solid bars) in the
presence of optimal concentrations of IL-4 or IL-12. Proliferation was
assessed by [3H]thymidine incorporation after 48 hr in culture. (B)
CD28-mediated costimulation, but not IL-2, reverses the Fas responsiveness of naı̈ve cells. Cells were cultured as in A except that the
growth factor IL-2 (10 ng兾ml) or anti-CD28 antibody (5 g兾ml) was
added instead of differentiation cytokines.
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entire population of CD4⫹ T cells from the immunized mice
was considered ‘‘memory.’’ The phenotypes of the cell populations were not as homogenous as in previous experiments on
normal (nontransgenic) mice, where stringent fractionation
was employed (Fig. 6A; compare with Fig. 1). Although T cells,
which lack the transgenic idiotype, are a small minority of the
total T cell population in the transgenic mice (27), 11–13% of
CD4⫹ T cells were V␤8.2⫺ (Fig. 6A). As much as 30% of TCR
transgenic T cells can convert to memory phenotype by
exposure to cross-reactive environmental antigens, in the
absence of specific antigen (41). The ‘‘naı̈ve’’ population in our
TCR transgenic mice included memory phenotype cells, presumably through exposure to environmental antigens of cells
bearing endogenous TCRs. The ‘‘memory’’ population also
included cells with a naı̈ve phenotype, probably because the
injected antigen failed to reach the entire complement of
peripheral T cells in the transgenic animal. However, a shift in
expression of CD44 and CD45RB occurred postimmunization,
and the cells no longer expressed activation markers by 24 days
after immunization (Fig. 6A). Furthermore, Fas expression
was comparable on the naı̈ve and memory populations (Fig.
6A). Thus, exposure to antigen changed the expression of
memory markers on the transgenic CD4⫹ T cells, but activation markers and Fas expression had returned to resting levels
by 24 days after immunization (Fig. 6A).
Despite the overlap of cell surface phenotypes in the ‘‘naı̈ve’’
and ‘‘memory’’ cells, the two populations manifested strikingly

FIG. 6. Fas responsiveness of TCR-transgenic CD4⫹ T cells shifts
from Fas-death-sensitive to Fas-costimulated after in vivo exposure to
HEL. Purified CD4⫹ T cells were prepared from cervical and axillary
lymph nodes of HEL TCR-transgenic mice that were uninjected
(HEL-naı̈ve) or were injected with HEL peptide 24 days previously
(HEL-exposed). (A) Cell surface phenotypes of HEL-naı̈ve (thin line)
and memory (24 days after HEL exposure; thick line) CD4⫹ TCRtransgenic T cells were determined by flow cytometry. Anti-V␤8.2
antibodies recognize the transgenic TCR ␤ chain; 87 and 89% of CD4⫹
cells were V␤8.2⫹ in HEL-naı̈ve and HEL-exposed mice, respectively.
Differences in phenotype between memory and naive cells occur only
in CD44 and CD45RB (memory markers) expression. (B) Memory
cells generated by in vivo exposure to antigen are costimulated by Fas.
HEL-naı̈ve (thin line) and memory (thick line) cells were cultured with
1 g兾ml of anti-CD3 antibody plus increasing concentrations of
anti-Fas antibody. (C) Fas ligation increases apoptotic death (⬍2n
DNA) in cultures of naı̈ve transgenic cells, but reduces apoptosis in
memory cell cultures. CD4⫹ TCR-transgenic T cells were cultured for
48 hr with anti-CD3 alone (dotted line), anti-CD3 plus anti-CD28
(thin, solid line), or anti-CD3 plus anti-Fas (thick line).
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different responses to Fas ligation. CD4⫹ ‘‘memory’’ cells from
antigen-exposed transgenic mice were costimulated by Fas in
a dose-dependent manner and, in fact, appeared more sensitive to Fas costimulation than did nontransgenic memory cells
(Fig. 6B). In contrast, the proliferative response of CD4⫹
‘‘naı̈ve’’ cells from unimmunized mice was not affected overall
by Fas ligation (Fig. 6B). However, Fas ligation increased the
amount of apoptotic cell death among the ‘‘naı̈ve’’ cells and
decreased apoptosis among the ‘‘memory’’ cells (Fig. 6C). This
result suggests that the apparent lack of Fas-mediated inhibition of naı̈ve cell proliferation (Fig. 6B) is due to increased
naı̈ve cell death, on the one hand, and increased proliferation
of contaminating memory cells, on the other. In agreement
with previously published data, when T cells were collected
early after antigen administration (within 2 weeks), T cells still
displayed activation markers and Fas ligation resulted in
marked cell death of the activated T cells, presumably by the
well characterized phenomenon of Fas-mediated AICD (5–7)
(data not shown).
Thus, CD4⫹ T cells from TCR-transgenic mice reveal that
preantigen-exposure naı̈ve cells are susceptible to Fasmediated death (Fig. 6C) whereas postexposure memory cells
are costimulated by Fas (Fig. 6B). These results are consistent
with experiments using stringently fractionated T cells from
nontransgenic mice.

DISCUSSION
A Dichotomy in the CD4ⴙ T Cell Response to Fas Ligation.
We have shown opposite outcomes of Fas ligation, namely,
death vs. increased proliferation, in naı̈ve versus memory
CD4⫹ T cells. We have used two independent systems to
confirm our results. In the first, naı̈ve and memory CD4⫹ T
cells were defined phenotypically and obtained from a common starting population of freshly isolated, normal lymphoid
cells. Naı̈ve and memory populations cultured under identical
conditions displayed opposite responses to Fas ligation. In the
second system, a functional definition of naı̈ve and memory
was employed, based on exposure to antigen in a TCRtransgenic mouse model. In this model, antigen was administered in vivo to produce a pool of physiologically generated,
antigen-specific memory cells, and the transgenic CD4⫹ T cells
were not subjected to phenotype-based fractionation before
Fas ligation and culture. Results obtained in both systems
confirm that the outcome of Fas ligation is fundamentally
different between a naı̈ve and a memory T cell. In the absence
of exogenous rescue signals, the default response of a naı̈ve
CD4⫹ T cell to Fas ligation in conjunction with activation
signals is apoptosis. In contrast, memory T cells expand more
rapidly as a consequence of Fas ligation with an antigenic
signal. Previous work has shown that human peripheral blood
T cells are costimulated by Fas ligation during anti-CD3induced proliferation (25). Unfractionated mouse T cells also
can be costimulated by Fas. The findings presented here
suggest that in both cases, the cells being costimulated and
exhibiting increased proliferation are the antigen-experienced
memory cells within the total peripheral T cell population.
Memory cells acquire altered phenotypic and functional
characteristics as they leave the naı̈ve (or activated cell)
pool(s), including differential cell surface expression of numerous molecules, loss of dependence on costimulation for
efficient and sustained proliferation, and decreased threshold
for activation (3). Such functional differences likely reflect
altered levels or activities of intracellular mediators, some of
which may impinge upon the Fas-signaling cascades and allow
the cell to respond to identical Fas ligation events with
opposite physiological outcomes. In particular, FLIP (the
FLICE-inhibitory protein), which blocks Fas-induced death by
preventing coupling of Fas to the downstream caspase cascades
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(42), is differentially regulated in T cells during activation (40)
and may be expressed at higher levels in memory cells.
A Model for Fas-Dependent Peripheral Tolerance. Mice and
humans with defective Fas expression or function are highly
susceptible to autoimmune disease (16, 17, 21–23). In the
absence of functional Fas, AICD occurs to a lesser extent and
with delayed kinetics than in normal individuals (43–46).
However, lymphoaccumulation resulting from defective AICD
does not explain the increased frequency of self-reactive clones
(15) and the development of overt autoimmunity. The Fasdependent death of naı̈ve cells described here is distinct from
Fas-dependent AICD, which requires prior clonal expansion
of effector cells (47) and is resistant to CD28-mediated
costimulation (14). In contrast, CD28-mediated costimulation
of naı̈ve cells not only prevents Fas-induced apoptosis, but
allows Fas engagement to augment the CD3-induced proliferative response. Our data suggest that Fas acts at an early
‘‘checkpoint’’ in clonal survival, before significant clonal expansion, by inducing death of naı̈ve cells if these cells do not
receive a costimulatory signal with the initial antigen signal.
Our findings provide experimental evidence for Fas-mediated
clonal abortion as a mechanism behind the ‘‘two-signal’’
hypothesis of peripheral tolerance. According to the two-signal
hypothesis, CD4⫹ T cells fail to proliferate if they are activated
by signal 1 (antigen) in the absence of signal 2 (a costimulatory
signal), as occurs during T cell recognition of a self-antigen on
a non-antigen-presenting cell (48). Our data provide experimental evidence of a mechanism for clonal abortion of naı̈ve
cells activated in the absence of costimulation and, hence, a
mechanism for Fas-dependent peripheral tolerance. Furthermore, our findings demonstrate that memory cells are not
susceptible to Fas-mediated death and, in fact, are costimulated by exogenous Fas ligation. Although Fas-mediated costimulation is not an absolute requirement for a primary
immune response (14), Fas-mediated costimulation may contribute to the increased efficiency and accelerated kinetics
displayed during memory responses.
Clearly, multiple mechanisms to ensure peripheral tolerance
operate in normal individuals. Redundancy in peripheral
tolerance mechanisms is suggested by the fact that not all
children with mutations in Fas develop the autoimmune
lymphoproliferative syndrome (ALPS), despite manifesting
defective apoptosis (21–23). Similarly, the lpr mutation leads to
overt autoimmunity only when expressed on susceptible genetic backgrounds (18). However, incorporating the notion
that Fas controls an early checkpoint in clonal expansion of
naı̈ve T cells, as well as clonal downsizing by AICD, provides
a mechanism for specific Fas-mediated deletion of potentially
self-reactive cells.
Paths to Autoimmunity. Our data suggest three mechanisms
of Fas-dependent predisposition to autoimmunity. First, individuals with defective Fas expression or function, such as lpr
mice and children with ALPS, not only manifest lymphadenopathy, which can be explained by defective AICD, but also
develop a high frequency of autoreactive clones and clinical
autoimmune symptoms (19, 21–23). In the absence of Fas,
naı̈ve cells activated without costimulation will not be eliminated. Clonal expansion of naı̈ve cells with autoreactive potential will no longer be aborted selectively, resulting in an
abnormally high frequency of activated, potentially autoreactive T cells, which could lead to overt disease in susceptible
individuals. Second, in individuals with normal Fas expression
and function, our data suggest that early Fas-mediated peripheral tolerance could be bypassed in the presence of high levels
of IL-4 or IL-12. A chronic inflammatory lesion secreting
differentiation cytokines therefore may provide an environment conducive to the outgrowth of potentially self-reactive
clones, because naı̈ve cells would lose sensitivity to Fasmediated death and gain the capacity for Fas costimulation
while in an environment rich in self-antigens released from
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damaged tissues. This may be a basis for epitope spreading
during experimentally induced and clinical autoimmune diseases and, perhaps, also in the gradual development of multiple organ involvement during autoimmunity (49–52). Third,
autoimmunity may arise through reactivation of memory cells,
because they lack sensitivity to Fas-mediated death even in the
absence of CD28 costimulation. Autoimmunity arising from
antigen cross-reactivity has been examined extensively, but the
mechanisms by which it occurs are poorly understood (53, 54).
Damaging responses may arise when cross-reactivity between
self- and foreign antigens allows a pool of memory cells,
generated in response to foreign antigens, to expand efficiently
in response to self-antigen, helped instead of hindered by Fas
expression.
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